Abstract
Spasticity is common after stroke and other neurological conditions and causes considerable limitations of movement, activities of daily living and participation. Interaction with other components of the upper motor neurone syndrome (UMNS) and the heterogeneity of patients' presentations together with limited tools for outcome measurement have hampered the production of randomised controlled trial data for management strategies. Specialist multi-disciplinary goal-centered management programmes are the mainstay of treatment.Pharmacological therapies have limited effect, and physical and positional management arecrucial. Targeted intramuscular botulinum toxin injection is now the most popular pharmacological treatment. Intrathecal therapies also play a lesser role. A team approach and holistic assessment are essential to beneficial outcomes. © The Author 2013. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved.
Author supplied keywords
Cite
CITATION STYLE
Graham, L. A. (2013, July). Management of spasticity revisited. Age and Ageing. https://doi.org/10.1093/ageing/aft064
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.